Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in bergmann glia | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 93 | 0.85 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 10311
Sealed predictions
- NCAM2 in oligodendrocytes, braak-0.19 (p 0.631) → +0.18 (p 0.638)receipt 10317
- NCAM2 in dopamine neurons, braak+0.37 (p 0.329) → -0.54 (p 0.136)receipt 10318
Swarm cases
receipt 10318: NCAM2 in dopamine neurons, braak
- power
- full sample -0.02 (p 0.942, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.04 (p 0.888, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.715, n 18). could be the mix.
- skeptic
- leave-one-out range -0.15 to +0.10, sign flips 6; without severely affected donors -0.02 (p 0.942, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NCAM2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 10317: NCAM2 in oligodendrocytes, braak
- power
- full sample +0.03 (p 0.922, n 18), 95% CI -0.45 to +0.49. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.06 (p 0.814, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.26 (p 0.298, n 18). could be the mix.
- skeptic
- leave-one-out range -0.10 to +0.14, sign flips 4; without severely affected donors +0.03 (p 0.922, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NCAM2 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts